Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
GLP-1 receptor agonists stimulate GLP-1R to promote insulin secretion, whereas DPP4 inhibitors slow GLP-1 degradation. Both approaches are incretin-based therapies for T2D. In addition to GLP-1 analogs, small nonpeptide GLP-1RAs such as LY3502970, TT-OAD2, and PF-06882961 have been considered as possible therapeutic alternatives. Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra are plants rich in cyclopeptides with hypoglycemic effects. Our previous study demonstrated the potential of their cyclopeptides for DPP4 inhibition. Reports of cyclic setmelanotide as an MC4R (GPCR) agonist and cyclic α-conotoxin chimeras as GLP-1RAs led to docking studies of these cyclopeptides with GLP-1R. Heterophyllin B, Pseudostellarin B, Cyclolinopeptide B, Cyclolinopeptide C, Drymarin A, and Diandrine C are abundant in these plants, with binding affinities of −9.5, −10.4, −10.3, −10.6, −11.2, and −11.9 kcal/mol, respectively. The configuration they demonstrated established multiple hydrogen bonds with the transmembrane region of GLP-1R. DdC:(cyclo)-GGPYWP showed the most promising docking score. The results suggest that, in addition to DPP4, GLP-1R may be a hypoglycemic target of these cyclopeptides. This may bring about more discussion of plant cyclopeptides as GLP-1RAs. Moreover, peptides derived from the HB precursor (IFGGLPPP), including IFGGWPPP, IFPGWPPP, IFGGYWPPP, and IFGYGWPPPP, exhibited diverse interactions with GLP-1R and displayed backbones available for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 (a) GLP-1R and the G-protein (PDB:6X19). (b) GLP-1 (red alpha helix, the original ligand of GLP-1R)/GLP-1R (transmembrane region) complex (PDB:6X18). (c) Important amino acid residues in the transmembrane region (TM1-7) of GLP-1R (PDB:6X19). Ser31, Tyr205, Gln234, Arg310, Arg190, Glu364, and Leu388, shown in orange, delineate the approximate boundaries of the active site. Asn300, Lys197, Tyr148, and Tyr145, shown in red, are the residues involved in the important hydrogen bonds and π–π interaction network in the middle section. Tyr220 and Gln221, shown in green, are located on ECL1. The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21]. The amino acids marked on the vertical axis on both sides and the horizontal axis on the bottom can be used as reference axes for analyzing the configuration of GLP-1R agonists. TM2 can also serve as a reference axis for configurational analysis of GLP-1RAs.](https://figures.cochat.ai/paper-figures/9a931190fd3f4cde90e0bc6dba1b9b1f/investigating-potential-glp-1-receptor-agonists-in-cyclopeptides-from-figure-1.jpg)














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Automatic atom type and bond type perception in molecular mechanical calculations
Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2005.12.005 · Cited by 5,477 · cited 1×
“Charges were computed using ANTECHAMBER [59].”
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“Glucagon-like peptide 1 (GLP-1) and glucosedependent insulinotropic polypeptide (GIP) are two important incretin hormones that help maintain blood glucose homeostasis [2,3].”
BackgroundArnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. A., Campopiano, D. J., Challis, G. L., Clardy, J., et al. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20085f · Cited by 2,076
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Exenatide (Byetta®, Bydureon®) is a synthetic version of exendin-4 and the first hypoglycemic drug classified as a GLP-1 analog [14].”
BackgroundThe Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“Novel semaglutide (Ozempic®) incorporates an absorption enhancer, further realizing the possibility of oral administration [8,15].”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 2×
“Semaglutide is being evaluated as a weight-loss drug for obese subjects without diabetes [11].”
BackgroundUnderstanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570 · cited 1×
“Unlike passive transport, cell-penetrating peptides (CPPs) consisting of three to four arginine residues and one to two hydrophobic residues can induce deformation of the cell membrane and then be taken up by cells via endocytosis [49].”
BackgroundCut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425 · cited 3×
“, with a large active region, cyclopeptides may be able to exert their structural properties [44].”
BackgroundTan, N.-H., & Zhou, J. (2006) · Chemical Reviews · doi:10.1021/cr040699h · Cited by 385
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302 · cited 1×
“Compared with α-MSH, setmelanotide can effectively activate the defective MC4R, which has been proven to help with weight control of the MC4R-variant carrier [27].”
BackgroundNauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295 · cited 1×
“The active sites of the DPP4 and GLP-1 receptors, both targets of incretin-based therapy, are large enough to accommodate these plant-derived cyclopeptides [43,44].”
BackgroundRecent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265 · cited 3×
“Novel semaglutide (Ozempic®) incorporates an absorption enhancer, further realizing the possibility of oral administration [8,15].”
BackgroundEfficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.013 · Cited by 251 · cited 2×
“According to a meta-analysis, DPP4 inhibitors and GLP-1R agonists affect glucose-lowering and weight control, but GLP-1R agonists are more effective than DPP4 inhibitors [6].”
BackgroundStructural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · cited 5×
“The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21].”
BackgroundInfluentialKoole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., & Sexton, P. M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065664 · Cited by 223 · cited 1×
“, it was found that quercetin selectively modulates calcium (Ca2+) signaling in the presence of truncated GLP-1 but has no effect on cAMP accumulation [52].”
BackgroundDifferential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.020 · Cited by 222
Improving oral bioavailability of cyclic peptides by N-methylation
Räder, A. F. B., Reichart, F., Weinmüller, M., & Kessler, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.031 · Cited by 215 · cited 1×
“Methylated cyclopeptides may exhibit accelerated passive transport when moving across membranes [48].”
BackgroundManandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198 · cited 1×
“The crystal structure of the complex of exendin-4 and GLP-1R shows that except for a part of the C-terminus, exendin-4 still adopts an α-helical conformation, and its binding site is similar to that of GLP-1 [16].”
BackgroundCrystal structure of the GLP-1 receptor bound to a peptide agonist
Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., et al. (2017) · Nature · doi:10.1038/nature22800 · Cited by 197 · cited 5×
“The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21].”
BackgroundInfluentialPan, A., Sun, J., Chen, Y., Ye, X., Li, H., Yu, Z., Wang, Y., Gu, W., Zhang, X., Chen, X., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001148 · Cited by 194
Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective
Bockus, A. T., McEwen, C. M., & Lokey, R. S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313070005 · Cited by 187 · cited 1×
“Commonly, nonpolar cyclopeptides enter cells via passive transport [46,47].”
BackgroundQuoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., & Dalle, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067207 · Cited by 187 · cited 1×
“β-Arrestin 1-mediated ERK1/2 activation may also be beneficial in protecting β-cells from apoptosis [3,25].”
BackgroundGlucagon-like peptide 1 and appetite
Dailey, M. J., & Moran, T. H. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.008 · Cited by 186 · cited 1×
“GLP-1R activation in the central hypothalamus has been shown to promote satiety, thereby reducing food intake and slowing gastric emptying [9].”
BackgroundAhlbach, C. L., Lexa, K. W., Bockus, A. T., Chen, V., Crews, P., Jacobson, M. P., & Lokey, R. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.78 · Cited by 178 · cited 1×
“Commonly, nonpolar cyclopeptides enter cells via passive transport [46,47].”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · cited 1×
“GLP-1R agonists also have been observed to improve endothelial dysfunction that may occur in diabetic patients through blood-flow-mediated vasodilation [12].”
BackgroundThe Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.023 · Cited by 164
Activation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164 · cited 5×
“Its backbone extends from Lys197 to Tyr220, sitting between TM2, TM3, and ECL1 [24].”
BackgroundInfluentialLiraglutide: A New Option for the Treatment of Obesity
Nuffer, W. A., & Trujillo, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1639 · Cited by 146 · cited 1×
“The higher dose of liraglutide (3 mg) under the trade name Saxenda® has been approved to treat overweight and weight-related diseases [10,11].”
BackgroundCyclic peptide oral bioavailability: Lessons from the past
Wang, C. K. L., & Craik, D. J. (2016) · Biopolymers · doi:10.1002/bip.22878 · Cited by 129 · cited 1×
“Unmethylated nonpolar cyclopeptides may stay in the cell membrane for some time before passing through, and this membrane crossing process may provide an opportunity to facilitate their interaction with GLP-1R [50].”
BackgroundYu, J., Gimenez, L. E., Hernandez, C. C., Wu, Y., Wein, A. H., Han, G. W., McClary, K., Mittal, S. R., Burdsall, K., Stauch, B., et al. (2020) · Science · doi:10.1126/science.aaz8995 · Cited by 125 · cited 1×
“PDB:6W25 and PDB:7PIU show the structures of MC4R in complex with SHU9119 and setmelanotide (Ca2+ as a cofactor), respectively, demonstrating the ability of cyclic peptides (cyclopeptides) to interact well with multiple α-helices of GPCRs (Figure 3f) [28,29].”
BackgroundGodinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109 · cited 1×
“with type 2 diabetes may not be able to maintain glucose homeostasis due to reduced GLP-1 secretion or accelerated GLP-1 metabolism [4].”
BackgroundHe, J., Chen, L.-X., & Li, H. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.02.033 · Cited by 108 · cited 1×
“Compared to DPP4, the role of natural products on GLP-1R is much less discussed [42].”
BackgroundStructures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
Heyder, N. A., Kleinau, G., Speck, D., Schmidt, A., Paisdzior, S., Szczepek, M., Bauer, B., Koch, A., Gallandi, M., Kwiatkowski, D., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00569-8 · Cited by 102
Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
Bueno, A. B., Sun, B., Willard, F. S., Feng, D., Ho, J. D., Wainscott, D. B., Showalter, A. D., Vieth, M., Chen, Q., Stutsman, C., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0589-7 · Cited by 98 · cited 5×
“In order to coexist with GLP-1, LSN3160440 retreats to the vicinity of Lys202 and Leu142, as shown in PDB:6VCB [22].”
BackgroundInfluentialMolecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
Cong, Z., Chen, L.-N., Ma, H., Zhou, Q., Zou, X., Ye, C., Dai, A., Liu, Q., Huang, W., Sun, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24058-z · Cited by 89 · cited 1×
“UK1 (PDB:6X19) and V6G (PDB:6XOX) are the ligands of GLP-1R with similar structures [17,21,23,24].”
BackgroundMani, U. V., Mani, I., Biswas, M., & Kumar, S. N. (2011) · Journal of Dietary Supplements · doi:10.3109/19390211.2011.593615 · Cited by 85
Hsieh, P., Chang, F., Lee, K., Hwang, T., Chang, S.-M., & Wu, Y. (2004) · Journal of Natural Products · doi:10.1021/np0400196 · Cited by 74
Yang, D., de Graaf, C., Yang, L., Song, G., Dai, A., Cai, X., Feng, Y., Reedtz-Runge, S., Hanson, M. A., Yang, H., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721977 · Cited by 60
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 58 · cited 1×
“Moreover, studies have demonstrated that GLP-1R agonists can reduce the risk of proteinuria and kidney disease progression [13].”
BackgroundChemistry, pharmacology and analysis of Pseudostellaria heterophylla: a mini-review
Hu, D., Shakerian, F., Zhao, J., & Li, S. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0243-z · Cited by 55 · cited 1×
“heterophylla can be used to improve fatigue, polydipsia, lung diseases, and physical fitness [30,36].”
BackgroundCoopman, K., Wallis, R., Robb, G., Brown, A. J. H., Wilkinson, G. F., Timms, D., & Willars, G. B. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1160 · Cited by 51
Orbitides from flaxseed (Linum usitatissimum L.): A comprehensive review
Shim, Y. Y., Song, Z., Jadhav, P. D., & Reaney, M. J. T. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.09.007 · Cited by 48 · cited 1×
“Studies have shown that it has antidiabetic, anticancer, antimalaria, cardioprotective, and immunomodulatory properties [37].”
BackgroundChen, J., Pang, W., Shi, W., Yang, B., Kan, Y., He, Z., & Hu, J. (2016) · Molecules · doi:10.3390/molecules21091233 · Cited by 40
Haldar, P. K., Patra, S., Bhattacharya, S., & Bala, A. (2020) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_98_19 · Cited by 34 · cited 1×
“Compared with the diabetes group, the β-cell density of the pancreatic tissue in the treatment group increased [35].”
Lu, F., Yang, H., Lin, S., Zhao, L., Jiang, C., Chen, Z. Z., Liu, Y., Kan, Y., Hu, J., & Pang, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00850 · Cited by 34 · cited 1×
“heterophylla can be used to improve fatigue, polydipsia, lung diseases, and physical fitness [30,36].”
BackgroundKounnis, V., Chondrogiannis, G., Mantzaris, M. D., Tzakos, A. G., Fokas, D., Papanikolaou, N. A., Galani, V., Sainis, I., & Briasoulis, E. C. (2015) · PubMed · Cited by 31
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists
Swedberg, J. E., Schroeder, C. I., Mitchell, J. M., Durek, T., Fairlie, D. P., Edmonds, D. J., Griffith, D. A., Ruggeri, R. B., Derksen, D. R., Loria, P. M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.046 · Cited by 26 · cited 1×
“found that monocyclic or bicyclic α-conotoxin peptidomimetic chimeras act as potent agonists of GLP-1R [26].”
BackgroundSu, K., Zhu, F., Guo, L., Zhu, Y., Li, W., & Xiong, X. (2013) · 中医杂志:英文版 · doi:10.1016/s0254-6272(13)60137-5 · Cited by 24
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein
Li, Q., Ma, L., Yi, D., Wang, H., Wang, J., Zhang, Y., Guo, Y., Li, X., Zhou, J., Shi, Y., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.020 · Cited by 21 · cited 1×
“, the cyclic peptide Ac-cyclo (CDDFFVYC)-NH2 and linear Ac-DDFFVY-NH2) to inhibit the entry of the Ebola pseudotype virus by targeting the GP protein [56].”
BackgroundThe Biosynthesis of Heterophyllin B in Pseudostellaria heterophylla From prePhHB-Encoded Precursor
Zheng, W., Zhou, T., Li, J., Jiang, W., Zhang, J., Xiao, C., Wei, D., Yang, C., Xu, R., Gong, A., et al. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01259 · Cited by 21
Liao, H.-J., & Tzen, J. T. C. (2022) · Metabolites · doi:10.3390/metabo12050387 · Cited by 18 · cited 1×
“The docking configuration demonstrates that these cyclopeptides can approach and interact with important amino acids near the catalytic center [45].”
BackgroundSelf-citationHsieh, P., Chang, F., Wu, C., Wu, K., Li, C., Wang, W., Gu, L., & Wu, Y. (2004) · Helvetica Chimica Acta · doi:10.1002/hlca.200490017 · Cited by 17
First Total Synthesis and Pharmacological Potential of a Plant Based Hexacyclopeptide.
Dahiya, R., Singh, S. K., Gupta, S. V., Sutariya, V. B., Bhatia, D., Mourya, R., Chennupati, S. V., & Sharma, A. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100643 · Cited by 12
Cyclopeptides design as blockers against HCV p7 channel in silico
Pang, S., Zhao, R., Wang, S., & Wang, J. (2019) · Molecular Simulation · doi:10.1080/08927022.2019.1641604 · Cited by 2 · cited 1×
“, observed that cyclic-4-Asp cooperates with the hydrophobic pocket in the conical region as an HCV p7 channel blocker [58].”
Background
Cited by
Legume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges
Hu, K., Huang, H., Li, H., Wei, Y., & Yao, C. (2023) · Nutrients · doi:10.3390/nu15051096 · Cited by 71
“Liraglutide is a once-daily GLP-1 analogue, whose homology of amino acids sequence with human GLP-1 is 97% [30].”
BackgroundBinding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“…a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33–35].”
Yang, Y., Wen, L., Jiang, Z.-Z., Chan, B. C.-L., Leung, P., Wong, C. K., & Tan, N.-H. (2025) · Molecules · doi:10.3390/molecules30122521 · Cited by 15
“[58]”
InfluentialQin, X., Wang, F., Xie, D., Zhou, Q., Lin, S., Lin, W., & Li, W. (2025) · Plant Communications · doi:10.1016/j.xplc.2025.101315 · Cited by 14
“Moreover, HB and its derivatives act as dipeptidyl peptidase IV inhibitors and GLP-1 receptor agonists which have been considered therapeutic alternatives for treating type 2 diabetes (Liao and Tzen, 2022a, 2022b).”
Metadata
- Authors
- Liao, H.-J., & Tzen, J. T. C.
- Affiliations
- National Chung Hsing University (TW)
- Corresponding author
- Liao, Hui-Jun
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2022-06-15
- Volume
- 12
- Issue
- 6
- Pages
- 549
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC9227353
- OpenAlex
- W4283009481
- Cited by
- 21
- References
- 60
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 3 · 2023: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, cyclopeptides, type 2 diabetes, Pseudostellaria heterophylla, flax, DPP-4 inhibition, GLP-1 receptor, molecular docking, plant peptides, hypoglycemic activity, cyclic peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.